Topic: NASH

Non-Alcoholic Steatohepatitis

Apr 2023 | Assessment

Interventions of Interest: An independent appraisal committee narrowly voted that currently available evidence for resmetirom is adequate to demonstrate a net health benefit over lifestyle management, whereas current evidence for obeticholic acid was deemed inadequate to demonstrate a net health benefit. ICER analyses suggest resmetirom would achieve common thresholds for cost-effectiveness if priced between $39,600 – $50,100 […]

Primary Biliary Cholangitis & Non-Alcoholic Steatohepatitis

Jul 2016 | Assessment

Intervention of Interest: Obeticholic Acid (OCALIVA®, Intercept Pharmaceuticals, Inc.) Obeticholic acid (OCA) is a novel bile acid analogue that has shown positive effects on biochemical markers of liver function in phase II trials and was approved by the FDA for treatment of primary biliary cholangitis (PBC) after failure of ursodeoxycholic Acid (UDCA). Primary biliary cholangitis (PBC), […]

Non-Alcoholic Steatohepatitis

Oct 2020 | Assessment

ICER planned to assess the comparative clinical effectiveness and value of obeticholic acid (Intercept) for the treatment of non-alcoholic steatohepatitis (NASH). For questions, please contact Update as of July 1, 2020: ICER will not hold the August 2020 Midwest CEPAC public meeting to discuss the comparative clinical effectiveness and value assessment of obeticholic acid […]